296 related articles for article (PubMed ID: 30972613)
1. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
van Uden DJP; van Maaren MC; Bult P; Strobbe LJA; van der Hoeven JJM; Blanken-Peeters CFJM; Siesling S; de Wilt JHW
Breast Cancer Res Treat; 2019 Jul; 176(1):217-226. PubMed ID: 30972613
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
4. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
van Uden DJP; van Maaren MC; Strobbe LJA; Bult P; van der Hoeven JJ; Siesling S; de Wilt JHW; Blanken-Peeters CFJM
Breast Cancer Res; 2019 Oct; 21(1):113. PubMed ID: 31623649
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
[TBL] [Abstract][Full Text] [Related]
7. Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
Jiao D; Zhang J; Zhu J; Guo X; Yang Y; Xiao H; Liu Z
BMC Cancer; 2021 Feb; 21(1):138. PubMed ID: 33549037
[TBL] [Abstract][Full Text] [Related]
8. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
9. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
[TBL] [Abstract][Full Text] [Related]
10. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.
Fayanju OM; Ren Y; Greenup RA; Plichta JK; Rosenberger LH; Force J; Suneja G; Devi GR; King TA; Nakhlis F; Hyslop T; Hwang ES
Breast Cancer Res Treat; 2020 Feb; 180(1):207-217. PubMed ID: 31960171
[TBL] [Abstract][Full Text] [Related]
11. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
Haque W; Verma V; Hatch S; Suzanne Klimberg V; Brian Butler E; Teh BS
Breast Cancer Res Treat; 2018 Aug; 170(3):559-567. PubMed ID: 29693228
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study.
Wu SG; Zhang WW; Wang J; Dong Y; Sun JY; Chen YX; He ZY
Future Oncol; 2019 Feb; 15(5):507-516. PubMed ID: 30378451
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES
Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
Nakhlis F; Niman SM; Ueno NT; Troll E; Ryan S; Yeh E; Warren L; Bellon J; Harrison B; Iwase T; Carisa Le-Petross HT; Saleem S; Teshome M; Whitman GJ; Woodward WA; Overmoyer B; Tolaney SM; Regan M; Lynce F; Layman RM
Breast Cancer Res Treat; 2024 Apr; 204(2):289-297. PubMed ID: 38155272
[TBL] [Abstract][Full Text] [Related]
15. Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer-Treated with Neoadjuvant Systemic Therapy.
De Schepper M; Nguyen HL; Richard F; Rosias L; Lerebours F; Vion R; Clatot F; Berghian A; Maetens M; Leduc S; Isnaldi E; Molinelli C; Lambertini M; Grillo F; Zoppoli G; Dirix L; Punie K; Wildiers H; Smeets A; Nevelsteen I; Neven P; Vincent-Salomon A; Larsimont D; Duhem C; Viens P; Bertucci F; Biganzoli E; Vermeulen P; Floris G; Desmedt C
Cancer Res Commun; 2024 Jan; 4(1):186-199. PubMed ID: 38147006
[TBL] [Abstract][Full Text] [Related]
16. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer.
Grova MM; Strassle PD; Navajas EE; Gallagher KK; Ollila DW; Downs-Canner SM; Spanheimer PM
Ann Surg Oncol; 2021 Apr; 28(4):2182-2190. PubMed ID: 32974693
[TBL] [Abstract][Full Text] [Related]
18. Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer.
Palazzo A; Dellapasqua S; Munzone E; Bagnardi V; Mazza M; Cancello G; Ghisini R; Iorfida M; Montagna E; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2018 Aug; 18(4):328-335. PubMed ID: 29486983
[TBL] [Abstract][Full Text] [Related]
19. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
20. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database.
Kupstas AR; Hoskin TL; Day CN; Boughey JC; Habermann EB; Hieken TJ
Br J Surg; 2020 Jul; 107(8):1033-1041. PubMed ID: 32057107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
